C07K 16/10
Rna viruses
Official title: RNA viruses
C07K16/10 (Rna viruses) appears on 2,639 US grants and 4,099 published applications in this corpus.
Search patents in C07K- Granted patents
- 2,639
- Published applications
- 4,099
- Assignees
- 1,675
- Inventors
- 7,627
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 5 | 0 |
| 1987 | 10 | 0 |
| 1988 | 9 | 0 |
| 1989 | 12 | 0 |
| 1990 | 7 | 0 |
| 1991 | 10 | 0 |
| 1992 | 14 | 0 |
| 1993 | 22 | 0 |
| 1994 | 16 | 0 |
| 1995 | 16 | 0 |
| 1996 | 26 | 0 |
| 1997 | 57 | 0 |
| 1998 | 67 | 0 |
| 1999 | 56 | 0 |
| 2000 | 53 | 0 |
| 2001 | 48 | 9 |
| 2002 | 39 | 52 |
| 2003 | 37 | 82 |
| 2004 | 27 | 92 |
| 2005 | 31 | 74 |
| 2006 | 39 | 94 |
| 2007 | 41 | 76 |
| 2008 | 36 | 74 |
| 2009 | 51 | 99 |
| 2010 | 58 | 145 |
| 2011 | 43 | 130 |
| 2012 | 68 | 150 |
| 2013 | 71 | 118 |
| 2014 | 103 | 160 |
| 2015 | 81 | 140 |
| 2016 | 116 | 194 |
| 2017 | 104 | 183 |
| 2018 | 151 | 191 |
| 2019 | 159 | 203 |
| 2020 | 152 | 228 |
| 2021 | 157 | 237 |
| 2022 | 128 | 239 |
| 2023 | 126 | 343 |
| 2024 | 162 | 377 |
| 2025 | 127 | 255 |
| 2026 | 98 | 154 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Cell-receptor targeted exosomes6 Oct 2026US 12,751,930 B2City of Hope
- Immunostimulatory adjuvants6 Oct 2026US 12,752,000 B2Orionis Biosciences BV
- Use of SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies to treat COVID-196 Oct 2026US 12,753,417 B2The Feinstein Institutes for Medical Research
- Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2)6 Oct 2026US 12,754,184 B2Navigo Proteins GmbH
- Lassa virus-specific nanobodies and methods of their use29 Sep 2026US 12,747,284 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Click chemistry assisted cell surface engineering for restoring lentivirus entry8 Oct 2026US 2026/0308632 A1The Children’s Hospital of Philadelphia
- Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf)1 Oct 2026US 2026/0295009 A1Partner Therapeutics, Inc.
- Asymmetric circular tandem repeat proteins1 Oct 2026US 2026/0297166 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Tcr-mimic bispecific antibodies for hiv-11 Oct 2026US 2026/0297193 A1The Johns Hopkins University
- Engineered antibodies24 Sep 2026US 2026/0285948 A1Danisco US Inc.
Most cited
By later US patents
- Anti-PD-L1 antibodies, compositions and articles of manufacture459US 8,217,149 B2Genentech, Inc. · 2012
- Metal chelate conjugated monoclonal antibodies310US 4,472,509 A1984
- Immunoassay utilizing monoclonal high affinity IgM antibodies286US 4,879,219 AThe General Hospital Corporation · 1989
- Cells producing antibody compositions with increased antibody dependent cytotoxic activity247US 6,946,292 B2Kyowa Hakko Kogyo Co., Ltd. · 2005
- Chimeric receptor genes and cells transformed therewith196US 8,211,422 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012